在2020年EHA会议上,Michael J. Dickinson 就CD20-TCB在复发或难治性(R / R)非霍奇金淋巴瘤(NHL)中I期临床试验中的疗效和安全性做了口头报告(Abstract: S241 )。CD20-TCB(RG6026)是一种新型的T细胞接合双特异性抗体,包含两个CD20片段抗原...
Introduction: CD20‐TCB (RG6026) is a T‐cell‐engaging bispecific antibody with a novel "2:1" molecular format which preclinically showed greater avidity for CD20 antigen, combinability with other anti‐CD20 antibodies, and greater efficacy as compared to other CD20‐CD3 bispecific formats. NP...
描述: 格菲妥单抗。关键字: RO7082859 |RG 6026 |CD20-TCB;RO7082859 |RG 6026 |CD20-TCB | 原创作者:上海陶术生物科技有限公司 标签:格菲妥单抗 Glofitamab;格菲妥单抗RO7082859|||RG 6026|||CD20-TCB;RO7082859|||RG 6026|||CD20-TCB产品询价/message 留言框 感兴趣的产品: * 您的单位: * 您的...
The molecule is now scheduled to start clinical trial by December 2016. Disclosures Bacac: Roche: Employment, Equity Ownership, Patents & Royalties. Umaa:Roche: Employment, Equity Ownership, Patents & Royalties. Herter:Roche: Employment, Patents & Royalties. Colombetti:Roche: Employment. Sam:Roche...
CD20-TCB (RG6026) is a novel T-cell-engaging bispecific antibody whose “2:1” format possesses two CD20 binders in addition to a CD3 binder, enabling increased tumor antigen avidity, rapid T-cell activation, and enhanced tumor cell killing. NP30179 is a multicenter phase I dose escalation...
CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies Author links open overlay panelMarina Bacac PhD * 1, Pablo Umaña PhD 1, Sylvia Herter PhD * 1, Sara Colombetti PhD * 1, Johannes Sam PhD * 1, Marine Le Clech * 1, Anne ...